City File: ICI on hold
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MOST analysts have already slashed their estimates of ICI's profits ahead of Thursday's third-quarter figures. The nine- monthly pre-tax range is now around pounds 525m, with up to pounds 650m for the full year. Nevertheless, the details will be keenly scanned to see how badly the American market for Tenormin, a heart drug, has suffered from the expiry of its patents. Sales could be down by half, according to some reports. Nor is there likely to be much cheer as far as the core chemicals business is concerned, where commodity prices have been in free fall since the summer. But the share price, down by more than pounds 3.50 since its May peak, has largely discounted the declining outlook, and the shares are probably a hold given that we are (surely) near the bottom of the cycle.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments